Literature DB >> 20934287

Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis.

Tomotaka Tanaka1, Hideharu Okanobu, Yoshio Kuga, Yoshikazu Yoshifuku, Hatsue Fujino, Tomohiro Miwata, Takashi Moriya, Toshihiro Nishida, Toshihide Oya.   

Abstract

BACKGROUND AND
OBJECTIVE: Elevated/activated myeloid leucocytes, like the CD14(+)CD16(+) monocytes are sources of TNF-α, and therefore, selective depletion of these cells by granulocyte/monocyte (GM) adsorption (GMA) should promote remission or enhance drug efficacy. However, studies in ulcerative colitis (UC) reported contrasting efficacy, from an 85% to statistically insignificant level. We investigated patients' demography in responders and non-responders.
METHODS: In 120 UC patients, 61 steroid naive and 59 steroid dependent, we looked for entry clinical or endoscopic features to identify responders (or non-responders) to GMA. Patients received up to an 11 Adacolumn GMA sessions over 12 weeks. Patients were clinically and endoscopically evaluated, allowing each patient to serve as her/his own control. Immunohistochemistry on colonic biopsies was to reveal the impact of GMA on leucocyte infiltration of the mucosa.
RESULTS: Entry average clinical activity index (CAI) was 12.6, 10-16. An 80 of 120 patients responded (CAI≤4); 45 steroid naïve (73.8%) and 35 steroid dependent (59.3%). Over 900 biopsies were processed. Infiltrating leucocytes were overwhelmingly polymorphonuclear and macrophages around and within crypt abscesses. There was a marked reduction of infiltrating leucocytes in responders. Most non-responders had extensive colonic lesions with virtually no mucosal tissue left at the lesions.
CONCLUSIONS: Steroid naïve patients with short duration of UC were the best responders, while patients with deep colonic lesions and extensive loss of the mucosal tissue were non-responders.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20934287     DOI: 10.1016/j.gcb.2010.08.007

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  15 in total

Review 1.  The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review.

Authors:  H Hanai; Y Takeda; M Eberhardson; R Gruber; A R Saniabadi; O Winqvist; R Lofberg
Journal:  Clin Exp Immunol       Date:  2010-11-16       Impact factor: 4.330

2.  Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes.

Authors:  Naoki Yoshimura; Tokuma Tadami; Takaaki Kawaguchi; Minako Sako; Hiroshi Yoshimoto; Toshihiko Yamaka; Masakazu Takazoe
Journal:  J Gastroenterol       Date:  2011-09-14       Impact factor: 7.527

Review 3.  The three human monocyte subsets: implications for health and disease.

Authors:  Kok Loon Wong; Wei Hseun Yeap; June Jing Yi Tai; Siew Min Ong; Truong Minh Dang; Siew Cheng Wong
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

Review 4.  Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs.

Authors:  Abbi R Saniabadi; Tomotaka Tanaka; Toshihide Ohmori; Koji Sawada; Takayuki Yamamoto; Hiroyuki Hanai
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 5.  Glucose intolerance and diabetes mellitus in ulcerative colitis: pathogenetic and therapeutic implications.

Authors:  Giovanni Maconi; Federica Furfaro; Roberta Sciurti; Cristina Bezzio; Sandro Ardizzone; Roberto de Franchis
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

6.  Granulocyte-Monocyte Apheresis in Steroid-Dependent, Azathioprine-Intolerant/Resistant Moderate Ulcerative Colitis: A Prospective Multicenter Study.

Authors:  Gianni Imperiali; Arnaldo Amato; Maria Maddalena Terpin; Ivo Beverina; Aurora Bortoli; Massimo Devani; Chiara Viganò
Journal:  Gastroenterol Res Pract       Date:  2017-12-21       Impact factor: 2.260

Review 7.  Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future.

Authors:  Xiu-Li Chen; Jing-Wei Mao; Ying-De Wang
Journal:  World J Gastrointest Pathophysiol       Date:  2020-05-12

8.  Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone.

Authors:  Keiichi Tominaga; Masakazu Nakano; Mina Hoshino; Kazunari Kanke; Hideyuki Hiraishi
Journal:  BMC Gastroenterol       Date:  2013-03-01       Impact factor: 3.067

9.  Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA.

Authors:  Yoko Yokoyama; Mikio Kawai; Ken Fukunaga; Koji Kamikozuru; Kazuko Nagase; Koji Nogami; Tomoaki Kono; Yoshio Ohda; Masaki Iimuro; Nobuyuki Hida; Shiro Nakamura; Hiroto Miwa; Takayuki Matsumoto
Journal:  BMC Gastroenterol       Date:  2013-02-12       Impact factor: 3.067

10.  Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications.

Authors:  Tomotaka Tanaka; Shinichiro Sugiyama; Hirokazu Goishi; Tsuyoshi Kajihara; Morihisa Akagi; Toshio Miura
Journal:  BMC Gastroenterol       Date:  2013-08-20       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.